Our lead therapeutic program, NJA-730, is novel oligonucleotide drug that offers compelling licensing opportunities. The drug candidate has completed dosing of all subjects in its Phase 1 study in Australia, with no reporting of dose-limiting toxicities or other noteworthy findings at any evaluated doses, and NapaJen intends to initiate a proof-of-concept Phase 2 clinical trial of NJA-730 in acute GvHD in 2021 in both United States and Australia.
Contact NapaJen to Discuss Partnering Opportunities
If you are interested in exploring a collaboration or licensing opportunity with NapaJen, please contact:
Business Development Dept.